The UK-based pharmaceutical company Haleon will invest $54.2 million to upgrade its R&D facility in Richmond, which has helped birth or grow products such as Advil, Emergen-C and Robitussin.

Haleon PLC has completed the acquisition of an additional 33% equity interest in its China-based joint venture, Tianjin TSKF Pharmaceutical Co. Ltd, for approximately £0.5 billion. This move ...

(Reuters) - Consumer healthcare company Haleon said on Wednesday it will invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new ...